Literature DB >> 24053274

Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.

Seyedmojtaba Seyedmousavi1, Johan W Mouton, Paul E Verweij, Roger J M Brüggemann.   

Abstract

Voriconazole and posaconazole are extended-spectrum triazoles recommended for treatment, prophylaxis and salvage therapy of Aspergillus diseases. Over the past decade many papers have emerged supporting the use of therapeutic drug monitoring (TDM) for azole antifungals. TDM is used to tailor the exposure of a specific drug to the individuals to optimize treatment response and minimize side effects. We reviewed the pharmacokinetics and pharmacodynamics (PK-PD) characteristics of voriconazole and posaconazole. We present the available evidence on target concentrations defining maximal efficacy and minimal toxicity. Finally we provide some practical recommendations how to best perform TDM in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24053274     DOI: 10.1586/14787210.2013.826989

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  24 in total

1.  Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.

Authors:  Leighanne O Parkes; Matthew P Cheng; Donald C Sheppard
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

2.  Antifungal susceptibility patterns of opportunistic fungi in the genera Verruconis and Ochroconis.

Authors:  S Seyedmousavi; K Samerpitak; A J M M Rijs; W J G Melchers; J W Mouton; P E Verweij; G S de Hoog
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

3.  Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis.

Authors:  Arthur W Baker; Eileen K Maziarz; Christopher J Arnold; Melissa D Johnson; Adrienne D Workman; John M Reynolds; John R Perfect; Barbara D Alexander
Journal:  Clin Infect Dis       Date:  2020-01-01       Impact factor: 9.079

4.  Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.

Authors:  Masaaki Mori; Ryoji Kobayashi; Koji Kato; Naoko Maeda; Keitaro Fukushima; Hiroaki Goto; Masami Inoue; Chieko Muto; Akifumi Okayama; Kenichi Watanabe; Ping Liu
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

5.  Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Johan W Mouton; Willem J G Melchers; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

6.  In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Johan W Mouton; Willem J G Melchers; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

7.  Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.

Authors:  Ping Liu; Diane R Mould
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

8.  Intravenous and Oral Posaconazole Pharmacokinetics in a Five-Year-Old With Mucor: A Case Report and Review of the Literature.

Authors:  Matthew O Ruland; Tosha A Egelund; John S Ng; Scott M Bradfield; Eric F Egelund
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Nov-Dec

9.  Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.

Authors:  Michael J Dolton; Roger J M Brüggemann; David M Burger; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

10.  Screening of the central nervous system in children with invasive pulmonary aspergillosis.

Authors:  Emmi Broenen; Annelies Mavinkurve-Groothuis; Karin Kamphuis-van Ulzen; Roger Brüggemann; Paul Verweij; Adilia Warris
Journal:  Med Mycol Case Rep       Date:  2014-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.